{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:32:32Z","timestamp":1785439952802,"version":"3.56.0"},"reference-count":37,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Johnson &amp; Johnson Innovative Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Long-term clinical trials and real-world data have established a comprehensive risk\u2013benefit profile for ibrutinib, informing adverse event (AE) management strategies to optimize safety and efficacy. Methods: We retrospectively assessed the incidence of AEs of special interest and management strategies in all patients treated with ibrutinib for chronic lymphocytic leukemia (CLL) in Saskatchewan, Canada, since 2014. Results: Among 187 patients (median age 75.7 years, 63% male), the median time from ibrutinib treatment initiation to data cutoff was 3.1 years. Approximately two-thirds of patients received ibrutinib for relapsed CLL (33.7% second-line and 32.6% third-line and beyond), with 33.7% receiving it first-line. All patients initiated ibrutinib as monotherapy at 420 mg. AEs of interest were observed in 81.3% of patients, with 42.8% experiencing \u22652 AEs. No grade 5 AEs were reported. Among the 284 first-onset AEs observed in 152 patients, 90.8% were successfully managed, allowing treatment continuation. The median time to successful management ranged from 27.0 days (range: 12.5\u201373.0) for infections to 84.0 days (range: 55.0\u2013141.0) for hypertension. Both AE and discontinuation rates were comparable or favourable to previous reports. Conclusion: This real-world analysis suggests that ibrutinib may be safely used in the majority of CLL patients encountered in routine practice.<\/jats:p>","DOI":"10.3390\/curroncol32060296","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T06:16:03Z","timestamp":1747980963000},"page":"296","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ibrutinib in Elderly Patients with Chronic Lymphocytic Leukemia: Adverse Event Incidence, Management, and Outcomes in a Canadian Real-World Setting"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5673-9945","authenticated-orcid":false,"given":"Ibraheem","family":"Othman","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medical Oncology and Hematology, Allan Blair Cancer Centre, Regina, SK S4T 7T1, Canada"},{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Zahra (Mona)","family":"Moossavi","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Bayati","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2926-8919","authenticated-orcid":false,"given":"Yi Sin","family":"Chang","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubrandu","family":"Sanjoy","sequence":"additional","affiliation":[{"name":"Epidemiology and Performance Measurement, Saskatchewan Cancer Agency, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Grzyb","sequence":"additional","affiliation":[{"name":"Research Department, Saskatchewan Health Authority, Regina, SK S7K 0M7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5033-797X","authenticated-orcid":false,"given":"Eric","family":"Sy","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"},{"name":"Department of Critical Care, Saskatchewan Health Authority, Regina, SK S4P 0W5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Cropper","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Kassir","sequence":"additional","affiliation":[{"name":"Research Department, Saskatchewan Health Authority, Regina, SK S7K 0M7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-5771","authenticated-orcid":false,"given":"Waleed","family":"Sabry","sequence":"additional","affiliation":[{"name":"College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada"},{"name":"Division of Hematology, Department of Medical Oncology and Hematology, Saskatoon Cancer Centre, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"ref_1","unstructured":"Canadian Cancer Society (2024, October 29). What is Chronic Lymphocytic Leukemia?. Available online: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/chronic-lymphocytic-leukemia-cll\/what-is-chronic-lymphocytic-leukemia."},{"key":"ref_2","unstructured":"Lymphoma Canada (2024, October 29). About CLL & SLL. Available online: https:\/\/www.lymphoma.ca\/lymphoma\/cll-sll\/about-cll-sll\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"(2024, October 29). Imbruvica (Ibrutinib) Product Monograph. Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00071920.PDF."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"106335","DOI":"10.1016\/j.leukres.2020.106335","article-title":"Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada","volume":"91","author":"Huang","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-138887","article-title":"Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)","volume":"136","author":"Khelifi","year":"2020","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1182\/blood-2023-172977","article-title":"Real World Experience of Ibrutinib in an Ethnically Diverse Canadian Community Hospital","volume":"142","author":"Kuruvilla","year":"2023","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1016\/S2152-2650(24)01259-X","article-title":"CLL-076 Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"24","author":"Burger","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma","volume":"18","author":"Hillmen","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.clml.2024.05.009","article-title":"Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients with Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry","volume":"24","author":"Ghosh","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1007\/s00277-024-05921-7","article-title":"Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: A real-world analysis","volume":"103","author":"Nunes","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/10428194.2022.2148220","article-title":"Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program","volume":"64","author":"Mulligan","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e6953","DOI":"10.1002\/cam4.6953","article-title":"Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia","volume":"13","author":"Huntington","year":"2024","journal-title":"Cancer Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: Risk prediction, management, and clinical outcomes","volume":"100","author":"Archibald","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/s41375-024-02334-3","article-title":"Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation","volume":"38","author":"Gambril","year":"2024","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4330\/wjc.v16.i5.269","article-title":"Ibrutinib and atrial fibrillation: An in-depth review of clinical implications and management strategies","volume":"16","author":"Mohyeldin","year":"2024","journal-title":"World J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.2147\/DDDT.S377697","article-title":"Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical","volume":"16","author":"Dong","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.jemermed.2016.10.019","article-title":"A perfect storm: Tyrosine kinase inhibitor-associated polymorphic ventricular tachycardia","volume":"52","author":"Beyer","year":"2017","journal-title":"J. Emerg. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jacep.2016.07.004","article-title":"Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia","volume":"2","year":"2016","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jaccao.2023.03.005","article-title":"Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib","volume":"5","author":"Nakhoda","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2024-202096","article-title":"Cardiac Safety Profiles of First-Generation Vs. Second-Generation BTK Inhibitors: A Meta-Analysis","volume":"144","author":"Mushtaq","year":"2024","journal-title":"Blood"},{"key":"ref_29","unstructured":"(2024, November 15). Calquence (Acalabrutinib) Prescribing Informtaion, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/210259s011lbl.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1182\/bloodadvances.2024013348","article-title":"Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: Forget about selectivity but watch the clock","volume":"8","author":"Minotti","year":"2024","journal-title":"Blood Adv."},{"key":"ref_31","unstructured":"(2024, November 15). National Library of Medicine (ClinicalTrials.gov): Ongoing trials with ibrutinib in CLL, Available online: https:\/\/clinicaltrials.gov\/search?cond=CLL&intr=Ibrutinib."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1080\/10428194.2019.1602268","article-title":"Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice","volume":"60","author":"Hampel","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_35","first-page":"34","article-title":"Ibrutinib Dose Reductions and Discontinuations Patterns Among Patients with Chronic Lymphocytic Leukemia from a Large Community Medical Oncology Practice","volume":"136","author":"Du","year":"2020","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e3249","DOI":"10.1002\/hon.3249","article-title":"Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort","volume":"42","author":"Martino","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/296\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:38:50Z","timestamp":1760031530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["curroncol32060296"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32060296","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}